Luye Pharma Group Ltd.
Research Luye Pharma Group Ltd. (2186.HK) on Bullrun: market cap HKD 6.81B, P/E 21.3. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2186.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyHKD
- Market capHKD 6.81B
- P/E21.3
- Financial periodFY2025
- RevenueCNY 6.31B
- Revenue growth4.1%
- Net incomeCNY 618.75M
- Free cash flowCNY 780.44M
- Gross margin66.0%
Valuation Snapshot
latest market cap is HKD 6.81B; P/E is 21.3.
Peer valuation comparison
Latest P/E is 21.31x versus a Healthcare sector median of 21.69x.
Latest P/E is 21.31x versus a China median of 16.26x (31.0% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 6.31B | CNY 618.75M | CNY 780.44M | 66.0% | 0.13 | CNY 4.49B | CNY 9.42B | CNY 16.07B |
| FY2024 | CNY 6.06B | CNY 471.89M | -CNY 1.54B | 66.7% | 0.13 | CNY 4.94B | CNY 10.32B | CNY 14.15B |
| FY2023 | CNY 6.14B | CNY 532.61M | CNY 430.23M | 68.4% | 0.14 | CNY 3.24B | CNY 8.42B | CNY 12.53B |
| FY2022 | CNY 5.98B | CNY 604.81M | CNY 490.14M | 69.2% | 0.17 | CNY 2.32B | CNY 9.10B | CNY 10.18B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 6.81B | 21.3 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Luye Pharma Group Ltd.
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu, for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Luye Pharma Group Ltd.'s market cap?
Luye Pharma Group Ltd.'s market capitalization is HKD 6.81B.
What is Luye Pharma Group Ltd.'s P/E ratio?
Luye Pharma Group Ltd.'s price-to-earnings (P/E) ratio is 21.3.
What does Luye Pharma Group Ltd. do?
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu, for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia.